The Zhitong Finance App noticed that before the US stock market on Wednesday, the stock price of Novavax Pharmaceuticals (NVAX.US) once fell nearly 30%. Previously, the US FDA suspended its new drug application for COVID-19 and influenza combination vaccines and independent influenza vaccine candidates on the grounds that a trial participant had serious adverse events. As of press release, Novavax Pharmaceuticals fell 16.83% to $10.61.

The Zhitong Finance App noticed that before the US stock market on Wednesday, the stock price of Novavax Pharmaceuticals (NVAX.US) once fell nearly 30%. Previously, the US FDA suspended its new drug application for COVID-19 and influenza combination vaccines and independent influenza vaccine candidates on the grounds that a trial participant had serious adverse events. As of press release, Novavax Pharmaceuticals fell 16.83% to $10.61.